Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem?

Treatment of hepatitis C virus (HCV) infection has evolved greatly through the recent decade. The availability of direct-acting antiviral agents (DAAs) targeting the functional proteins of HCV has resulted in the introduction of DAA-based combination therapies, providing an optimal rate of treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharafi, Heidar, Alavian, Seyed Moayed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2018
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177567/
https://www.ncbi.nlm.nih.gov/pubmed/30310532
http://dx.doi.org/10.4254/wjh.v10.i9.543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177567/
https://www.ncbi.nlm.nih.gov/pubmed/30310532
http://dx.doi.org/10.4254/wjh.v10.i9.543

Ejemplares similares